Jasper Therapeutics is enabling cures through stem cell transplantation. The company is testing a c-Kit/ CD119 antibody (JSP-191) in phase 1/2 trials in urticaria (severe itch) and phase 2/3 in stem cell transplant applications. Jasper was founded out of Stanford and JSP-191 was invented and developed at Amgen. In May 2021 the company listed on Nasdaq with the ticker JSPR.